Concepts (157)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Plasmodium falciparum | 18 | 2013 | 144 | 1.800 |
Why?
|
| Biomedical Research | 4 | 2025 | 502 | 1.000 |
Why?
|
| Interinstitutional Relations | 1 | 2025 | 51 | 0.900 |
Why?
|
| Cooperative Behavior | 2 | 2025 | 269 | 0.830 |
Why?
|
| Malaria, Falciparum | 6 | 2013 | 90 | 0.800 |
Why?
|
| Merozoite Surface Protein 1 | 8 | 2010 | 34 | 0.790 |
Why?
|
| Education, Medical | 1 | 2024 | 118 | 0.780 |
Why?
|
| Precursor Cells, B-Lymphoid | 1 | 2022 | 4 | 0.760 |
Why?
|
| Toll-Like Receptor 7 | 1 | 2022 | 12 | 0.760 |
Why?
|
| Curriculum | 1 | 2024 | 318 | 0.710 |
Why?
|
| Antigens, Protozoan | 12 | 2002 | 74 | 0.680 |
Why?
|
| Antibodies, Protozoan | 12 | 2010 | 82 | 0.620 |
Why?
|
| Health Services, Indigenous | 1 | 2018 | 33 | 0.530 |
Why?
|
| Schools, Medical | 1 | 2018 | 208 | 0.470 |
Why?
|
| Metabolome | 1 | 2013 | 51 | 0.390 |
Why?
|
| Protozoan Proteins | 5 | 1994 | 191 | 0.380 |
Why?
|
| Metabolomics | 1 | 2013 | 95 | 0.380 |
Why?
|
| Minority Groups | 3 | 2025 | 690 | 0.370 |
Why?
|
| Erythrocytes | 1 | 2013 | 126 | 0.370 |
Why?
|
| Epitopes | 4 | 2010 | 157 | 0.360 |
Why?
|
| Research Personnel | 4 | 2025 | 206 | 0.330 |
Why?
|
| Protein Precursors | 3 | 1994 | 59 | 0.310 |
Why?
|
| Immunoglobulin M | 1 | 2010 | 86 | 0.310 |
Why?
|
| Immunoglobulin G | 1 | 2010 | 259 | 0.290 |
Why?
|
| Malaria Vaccines | 3 | 2010 | 21 | 0.260 |
Why?
|
| Humans | 16 | 2025 | 43102 | 0.250 |
Why?
|
| Leptospira | 1 | 2025 | 27 | 0.230 |
Why?
|
| Leptospirosis | 1 | 2025 | 31 | 0.230 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2025 | 120 | 0.220 |
Why?
|
| Lymphocyte Activation | 2 | 2022 | 249 | 0.220 |
Why?
|
| Adjuvants, Immunologic | 3 | 1994 | 117 | 0.210 |
Why?
|
| Antigens, Surface | 5 | 1994 | 52 | 0.200 |
Why?
|
| Genetic Variation | 1 | 2005 | 430 | 0.190 |
Why?
|
| Toll-Like Receptor 9 | 1 | 2022 | 9 | 0.190 |
Why?
|
| Receptors, Pattern Recognition | 1 | 2022 | 11 | 0.190 |
Why?
|
| Interleukin-4 | 1 | 2022 | 75 | 0.190 |
Why?
|
| Cytokines | 2 | 2022 | 678 | 0.180 |
Why?
|
| Public Health | 1 | 2025 | 424 | 0.170 |
Why?
|
| Ligands | 1 | 2022 | 388 | 0.170 |
Why?
|
| Peptide Fragments | 2 | 1993 | 307 | 0.170 |
Why?
|
| Cross Reactions | 4 | 2010 | 87 | 0.150 |
Why?
|
| Hawaii | 3 | 2025 | 2011 | 0.150 |
Why?
|
| United States | 3 | 2025 | 5205 | 0.150 |
Why?
|
| Cell Differentiation | 1 | 2022 | 638 | 0.150 |
Why?
|
| Behavioral Research | 1 | 2019 | 41 | 0.140 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 83 | 0.140 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 88 | 0.140 |
Why?
|
| Minority Health | 1 | 2019 | 95 | 0.140 |
Why?
|
| Colombia | 2 | 2010 | 31 | 0.140 |
Why?
|
| Baculoviridae | 3 | 2002 | 12 | 0.130 |
Why?
|
| Recombinant Proteins | 5 | 2010 | 518 | 0.130 |
Why?
|
| Animals | 17 | 2025 | 16992 | 0.120 |
Why?
|
| Alleles | 3 | 2010 | 352 | 0.120 |
Why?
|
| Genotype | 2 | 2010 | 800 | 0.110 |
Why?
|
| Major Histocompatibility Complex | 1 | 1994 | 29 | 0.110 |
Why?
|
| Cyclic ADP-Ribose | 1 | 2013 | 3 | 0.100 |
Why?
|
| Data Mining | 1 | 2013 | 30 | 0.100 |
Why?
|
| Hydrolysis | 1 | 2013 | 97 | 0.100 |
Why?
|
| Glycolysis | 1 | 2013 | 71 | 0.100 |
Why?
|
| Arginine | 1 | 2013 | 75 | 0.100 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2013 | 74 | 0.100 |
Why?
|
| Rabbits | 5 | 2008 | 278 | 0.090 |
Why?
|
| Mass Spectrometry | 1 | 2013 | 280 | 0.090 |
Why?
|
| Antibody Specificity | 5 | 2008 | 76 | 0.090 |
Why?
|
| Databases, Factual | 1 | 2013 | 341 | 0.090 |
Why?
|
| Seeds | 1 | 2010 | 46 | 0.080 |
Why?
|
| Papua New Guinea | 1 | 2010 | 21 | 0.080 |
Why?
|
| Cameroon | 1 | 2010 | 35 | 0.080 |
Why?
|
| Phosphorylation | 1 | 2013 | 986 | 0.080 |
Why?
|
| Arabidopsis | 1 | 2010 | 103 | 0.080 |
Why?
|
| Child | 2 | 2010 | 3443 | 0.080 |
Why?
|
| Gene Frequency | 1 | 2010 | 206 | 0.080 |
Why?
|
| Protozoan Vaccines | 3 | 1994 | 16 | 0.070 |
Why?
|
| Gene Expression Regulation | 1 | 1994 | 1070 | 0.070 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 5 | 2008 | 458 | 0.070 |
Why?
|
| HIV Infections | 1 | 2022 | 2586 | 0.070 |
Why?
|
| Amino Acid Sequence | 6 | 2008 | 1180 | 0.070 |
Why?
|
| Vaccines, Synthetic | 3 | 2008 | 80 | 0.070 |
Why?
|
| Cohort Studies | 2 | 2022 | 1759 | 0.070 |
Why?
|
| Adolescent | 2 | 2010 | 6081 | 0.060 |
Why?
|
| Infant | 1 | 2010 | 1175 | 0.060 |
Why?
|
| Mice | 7 | 1996 | 6644 | 0.060 |
Why?
|
| Zoonoses | 1 | 2025 | 21 | 0.060 |
Why?
|
| DNA | 1 | 1988 | 592 | 0.060 |
Why?
|
| Child, Preschool | 1 | 2010 | 1546 | 0.060 |
Why?
|
| Molecular Sequence Data | 5 | 2002 | 1542 | 0.050 |
Why?
|
| Male | 3 | 2025 | 23409 | 0.050 |
Why?
|
| Antibodies, Bispecific | 1 | 2002 | 5 | 0.050 |
Why?
|
| Granulocytes | 1 | 2022 | 26 | 0.050 |
Why?
|
| Immune Sera | 3 | 1992 | 56 | 0.050 |
Why?
|
| Female | 3 | 2025 | 24698 | 0.050 |
Why?
|
| Middle Aged | 2 | 2010 | 12222 | 0.050 |
Why?
|
| Incidence | 1 | 2025 | 1078 | 0.050 |
Why?
|
| Mice, Inbred Strains | 2 | 1994 | 114 | 0.050 |
Why?
|
| Fibrosis | 1 | 2022 | 169 | 0.050 |
Why?
|
| Actins | 1 | 2022 | 164 | 0.040 |
Why?
|
| Antibodies, Monoclonal | 2 | 1996 | 306 | 0.040 |
Why?
|
| Adult | 2 | 2010 | 13872 | 0.040 |
Why?
|
| Maryland | 1 | 2021 | 66 | 0.040 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2020 | 24 | 0.040 |
Why?
|
| T-Lymphocytes | 1 | 2002 | 386 | 0.040 |
Why?
|
| Phenotype | 1 | 2022 | 780 | 0.040 |
Why?
|
| Genome, Viral | 1 | 2020 | 119 | 0.040 |
Why?
|
| Young Adult | 1 | 2010 | 5080 | 0.040 |
Why?
|
| Research Support as Topic | 1 | 2019 | 89 | 0.040 |
Why?
|
| Mice, Inbred C57BL | 3 | 1992 | 1869 | 0.040 |
Why?
|
| Base Sequence | 2 | 1992 | 983 | 0.040 |
Why?
|
| Species Specificity | 2 | 1989 | 286 | 0.040 |
Why?
|
| Cultural Diversity | 1 | 2019 | 193 | 0.030 |
Why?
|
| Inflammation | 1 | 2022 | 758 | 0.030 |
Why?
|
| Aged | 1 | 2010 | 8214 | 0.030 |
Why?
|
| Immunization | 2 | 1992 | 94 | 0.030 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 1 | 1994 | 47 | 0.030 |
Why?
|
| Immunoblotting | 2 | 1996 | 181 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2022 | 3156 | 0.030 |
Why?
|
| Primates | 1 | 1994 | 39 | 0.030 |
Why?
|
| Haplotypes | 1 | 1994 | 197 | 0.030 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 1992 | 25 | 0.020 |
Why?
|
| Oligonucleotide Probes | 1 | 1992 | 21 | 0.020 |
Why?
|
| B-Lymphocytes | 1 | 1993 | 189 | 0.020 |
Why?
|
| Health Status Disparities | 1 | 2019 | 719 | 0.020 |
Why?
|
| Sequence Homology, Nucleic Acid | 1 | 1992 | 88 | 0.020 |
Why?
|
| Binding, Competitive | 1 | 1992 | 109 | 0.020 |
Why?
|
| Recombination, Genetic | 1 | 1992 | 95 | 0.020 |
Why?
|
| Fluorescent Antibody Technique | 1 | 1992 | 196 | 0.020 |
Why?
|
| Acetylmuramyl-Alanyl-Isoglutamine | 1 | 1991 | 1 | 0.020 |
Why?
|
| Lipid A | 1 | 1991 | 8 | 0.020 |
Why?
|
| Freund's Adjuvant | 1 | 1991 | 14 | 0.020 |
Why?
|
| Hybridomas | 2 | 2002 | 24 | 0.020 |
Why?
|
| Blotting, Western | 1 | 1992 | 883 | 0.020 |
Why?
|
| Antibody Formation | 1 | 1989 | 76 | 0.020 |
Why?
|
| Vaccination | 1 | 1992 | 355 | 0.020 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 1989 | 197 | 0.020 |
Why?
|
| Restriction Mapping | 1 | 1988 | 42 | 0.020 |
Why?
|
| Vaccines, Subunit | 1 | 2008 | 34 | 0.020 |
Why?
|
| Oligonucleotides | 1 | 1988 | 49 | 0.020 |
Why?
|
| Animals, Genetically Modified | 1 | 2008 | 100 | 0.020 |
Why?
|
| Vaccines | 1 | 1988 | 65 | 0.020 |
Why?
|
| Malaria | 1 | 1988 | 90 | 0.020 |
Why?
|
| Polymorphism, Genetic | 1 | 1988 | 201 | 0.020 |
Why?
|
| Water | 1 | 1988 | 316 | 0.020 |
Why?
|
| Muromonab-CD3 | 1 | 2002 | 1 | 0.010 |
Why?
|
| Single-Chain Antibodies | 1 | 2002 | 3 | 0.010 |
Why?
|
| Immunoglobulin Variable Region | 1 | 2002 | 22 | 0.010 |
Why?
|
| Neutrophil Activation | 1 | 2002 | 10 | 0.010 |
Why?
|
| Spodoptera | 1 | 2002 | 16 | 0.010 |
Why?
|
| Phagocytosis | 1 | 2002 | 86 | 0.010 |
Why?
|
| Macrophage Activation | 1 | 2002 | 61 | 0.010 |
Why?
|
| Killer Cells, Natural | 1 | 2002 | 104 | 0.010 |
Why?
|
| Interferon-gamma | 1 | 2002 | 269 | 0.010 |
Why?
|
| Transfection | 1 | 2002 | 532 | 0.010 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2002 | 384 | 0.010 |
Why?
|
| Cell Line | 1 | 2002 | 1410 | 0.010 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 1 | 1996 | 39 | 0.010 |
Why?
|
| Antibody Affinity | 1 | 1991 | 21 | 0.010 |
Why?
|
| Membrane Glycoproteins | 1 | 1991 | 224 | 0.010 |
Why?
|
| Peptides | 1 | 1991 | 372 | 0.000 |
Why?
|